跳至主要内容
临床试验/NCT07123909
NCT07123909招募中不适用

The Use of Sorption Technologies in Patients Receiving Program Hemodialysis With Inflammatory Syndrome

Botkin Hospital1 个研究点 分布在 1 个国家目标入组 60 人开始时间: 2025年6月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
60
试验地点
1
主要终点
Change from baseline in serum IL-6, pg/ml

研究概览

简要总结

Use of sorption technologies in patients undergoing maintenance hemodialysis with inflammatory syndrome and clinical manifestations of uremia

详细描述

This study will involve 30 hemodialysis patients selected based on examination results showing elevated C-reactive protein (CRP) and/or interleukin-6 (IL-6) levels. Participants will undergo hemoadsorption with the Jafron HA130 cartridge performed concurrently with hemodialysis: three times per week during the first month, twice per week during the second month, and once per week during the third month.

The following parameters will be assessed: inflammatory markers (CRP, IL-1, IL-6, IL-8, β2-microglobulin, free light chains of immunoglobulins), parathyroid hormone (PTH), standard biochemical blood tests (creatinine, urea, calcium, phosphorus, albumin, iron metabolism), and complete blood count. Analyses will be performed at baseline (before inclusion) and monthly thereafter.

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Adequate dialysis defined by a KT/V index ≥ 1.4
  • No active inflammatory process or infection
  • Age ≥ 18 years
  • Receiving standard hemodialysis regimen three times weekly, at least 4 hours per session
  • Participants with elevated interleukin-6 (IL-6) and/or C-reactive protein (CRP) levels exceeding local laboratory reference values

排除标准

  • Current use of steroids or immunosuppressive therapy
  • History of kidney transplantation
  • Diagnosis of cancer

结局指标

主要结局

Change from baseline in serum IL-6, pg/ml

时间窗: By the third month

次要结局

  • Change frome baseline in serum IL-1, pg/ml(Monthly for 3 months)
  • Change from baseline in ferritin, mcg/L(Monthly for 3 months)
  • Change from baseline in serum IL-8, pg/ml(Monthly for 3 months)
  • Change from baseline in serum IL-10, pg/ml(Monthly for 3 months)
  • Change from baseline in CRP, mg/L(Monthly for 3 months)
  • Change from baseline in free light chains, mcg/ml(Monthly for 3 months)
  • Change from baseline in PTH, pg/ml(Monthly for 3 months)
  • Change from baseline in saturated transferrin, TS%(Monthly for 3 months)
  • Change from baseline in blood urea nitrogen (BUN), mmol/L(Monthly for 3 months)
  • Change from baseline in creatinine, mg/dL(Monthly for 3 months)
  • Change from baseline in pruritus (Visual Analogue Scale)(Monthly for 3 months)
  • Change from baseline in calcium, mmol/L(Monthly for 3 months)
  • Change from baseline in β2-microglobulin, mg/L(Monthly for 3 months)
  • Change from baseline in serum iron, mcg/dL(Monthly for 3 months)
  • Change from baseline in albumin, g/L(Monthly for 3 months)
  • Change from baseline in phosphorus, mmol/L(Monthly for 3 months)
  • Change from baseline in hemoglobin (Hb), g/L(Monthly for 3 months)
  • Change from baseline in Hospital Anxiety and Depression Scale Score(Monthly for 3 months)

研究者

发起方
Botkin Hospital
申办方类型
Other
责任方
Principal Investigator
主要研究者

Evgeny Shutov

Head of the Nephrology Center, Botkin Hospital

Botkin Hospital

研究点 (1)

Loading locations...

相似试验